Navigation Links
Mach One Completes Note Exchange
Date:1/22/2009

BELGIUM, Wis., Jan. 22 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a biological solutions company that develops products that produce a positive long term benefit to the agricultural and consumer market, announced today that it has completed its Subordinated Note Swap of $1.5 million with an Investor.

Mach One issued the Original Note to facilitate the equipment purchase for its first production facility in Wisconsin. The Original Note had an amortization schedule that started after the completion of the equipment purchase. The new board upon review of that part of the capital structure did not see the need to start amortization during the Wisconsin facility startup stage so it proposed exchanging the Original Note for a Zero Coupon Convertible Note similar in structure to the Note issued in the Pacific Rim Foods Ltd. transaction.

Monte B. Tobin, Chairman and Chief Executive Officer of Mach One, said, "We are pleased that our board has taken an active role in assisting the company in matching its capital structure to its business model. We continue to execute on our business plan and are pleased with this recent capital change which when combined with the capital provided by Pacific Rim Foods Ltd, and the recent $500,000 and $1.5 million capital placement will allow Mach One to move forward on execution of its business model."

Tad Ballantyne, Director, said, "We are pleased to have a strategic Investor who recognizes the benefits to both parties of the Note exchange. We look forward to the strategic Investor's participation as a board member along with the addition of another board member from the announced Ceres Organic transaction. Both these anticipated board members have extensive experience in the 'healthy food' sector which is part of our mission of building a global company focusing on the 'health benefits to man and animal.' Execution of both capital fo
'/>"/>

SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
5. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
6. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
7. NeoStem Completes $500,000 Private Placement With Strategic Investor
8. Lilly Completes Cash Tender Offer for ImClone Systems
9. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
10. Accera, Inc. Completes $35 Million Series C Financing
11. OncoMed Pharmaceuticals Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... are quickly eliminated from the body. Scientists at the ... a kind of molecular balloon that swells and thus ... The TUM spin-off XL-protein GmbH has now started to ... People who suffer from hepatitis B are often treated ...
... WOBURN, Mass., Sept. 21 The Center for Business Intelligence ... the proceeds from their Alzheimer,s Drug Development Summit to the ... this week, September 21-25, 2009, in recognition of World Alzheimer,s ... Alzheimer,s associations, globally, to raise awareness and encourage citizens to ...
... NEW YORK, Sept. 21 Emissary Capital Group, ... (OTC Bulletin Board: SNBP) with a Buy rating and ... domestically as Dong Ying Pharmaceutical Co. Ltd., is a ... R&D, manufacture and distribution of biopharmaceutical products. The ...
Cached Biology Technology:Researchers prolong the plasma half-life of biopharmaceutical proteins 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 3Emissary Capital Group Initiates Coverage on Sinobiopharma 2
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... September 19, 2011 Dr. Martin Fregene, Director of ... Center has been tasked with leading the implementation of ... the Honourable Minister for Agriculture and Natural Resources. ... remain a co-Principal Investigator of BC Plus sharing that ...
... to producing the developmental differences displayed by social insects ... organismal function, a new study has found. ... different ways by varying the genes they express, ultimately ... permits organisms to operate successfully in their environments. A ...
... Cystic fibrosis (CF), a chronic disease that clogs the ... by a genetic defect in a chloride channel called ... not fully understand how or why this defect occurs, ... Children (SickKids) in Toronto, Ontario, Canada has found a ...
Cached Biology News:Danforth Center scientist recruited to spearhead cassava green revolution for Nigeria 2Danforth Center scientist recruited to spearhead cassava green revolution for Nigeria 3Fast-evolving genes control developmental differences in social insects 2Fast-evolving genes control developmental differences in social insects 3Unraveling a new regulator of cystic fibrosis 2
FEN-1 (B-4)...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: